In last trading session, Cue Biopharma Inc (NASDAQ:CUE) saw 0.55 million shares changing hands with its beta currently measuring 1.76. Company’s recent per share price level of $1.72 trading at -$0.06 or -3.37% at ring of the bell on the day assigns it a market valuation of $103.56M. That closing price of CUE’s stock is at a discount of -88.95% from its 52-week high price of $3.25 and is indicating a premium of 73.84% from its 52-week low price of $0.45. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.72 million shares which gives us an average trading volume of 656.33K if we extend that period to 3-months.

For Cue Biopharma Inc (CUE), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.19 in the current quarter.

Cue Biopharma Inc (NASDAQ:CUE) trade information

Upright in the red during last session for losing -3.37%, in the last five days CUE remained trading in the green while hitting it’s week-highest on Thursday, 11/07/24 when the stock touched $1.72 price level, adding 9.47% to its value on the day. Cue Biopharma Inc’s shares saw a change of -34.85% in year-to-date performance and have moved 13.16% in past 5-day. Cue Biopharma Inc (NASDAQ:CUE) showed a performance of 29.32% in past 30-days. Number of shares sold short was 1.95 million shares which calculate 1.99 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 6 to the stock, which implies a rise of 71.33% to its current value. Analysts have been projecting 2 as a low price target for the stock while placing it at a high target of 7. It follows that stock’s current price would drop -16.28% in reaching the projected high whereas dropping to the targeted low would mean a loss of -16.28% for stock’s current value.

Cue Biopharma Inc (CUE) estimates and forecasts

Statistics highlight that Cue Biopharma Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -1.15% of value to its shares in past 6 months, showing an annual growth rate of 34.23% while that of industry is 16.60. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 102.70% from the last financial year’s standing.

4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 1.52M for the same. And 4 analysts are in estimates of company making revenue of 5.23M in the next quarter. Company posted 1.13M and 1.82M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 10.55% during past 5 years.

Cue Biopharma Inc (NASDAQ:CUE)’s Major holders

Insiders are in possession of 0.55% of company’s total shares while institution are holding 25.95 percent of that, with stock having share float percentage of 26.09%. Investors also watch the number of corporate investors in a company very closely, which is 25.95% institutions for Cue Biopharma Inc that are currently holding shares of the company. BLEICHROEDER LP is the top institutional holder at CUE for having 2.86 million shares of worth $3.55 million. And as of 2024-06-30, it was holding 5.7849 of the company’s outstanding shares.

The second largest institutional holder is SLATE PATH CAPITAL LP, which was holding about 2.4 million shares on 2024-06-30. The number of shares represents firm’s hold over 4.8567 of outstanding shares, having a total worth of $2.98 million.